PT3286317T - Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne - Google Patents
Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenneInfo
- Publication number
- PT3286317T PT3286317T PT167220763T PT16722076T PT3286317T PT 3286317 T PT3286317 T PT 3286317T PT 167220763 T PT167220763 T PT 167220763T PT 16722076 T PT16722076 T PT 16722076T PT 3286317 T PT3286317 T PT 3286317T
- Authority
- PT
- Portugal
- Prior art keywords
- dynamin
- duchenne
- inhibitor
- treatment
- muscular dystrophy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
- C12Y306/05005—Dynamin GTPase (3.6.5.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305615.5A EP3085785A1 (en) | 2015-04-22 | 2015-04-22 | Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3286317T true PT3286317T (pt) | 2021-05-18 |
Family
ID=53005533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167220763T PT3286317T (pt) | 2015-04-22 | 2016-04-22 | Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10822400B2 (pt) |
| EP (2) | EP3085785A1 (pt) |
| JP (1) | JP6791877B2 (pt) |
| CN (1) | CN107532169B (pt) |
| AU (1) | AU2016251973B2 (pt) |
| CA (1) | CA2983211A1 (pt) |
| DK (1) | DK3286317T3 (pt) |
| ES (1) | ES2869978T3 (pt) |
| PT (1) | PT3286317T (pt) |
| WO (1) | WO2016170162A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10947540B2 (en) * | 2016-11-29 | 2021-03-16 | Association Institut De Myologie | Allele-specific silencing therapy for Dynamin 2-related diseases |
| WO2018115477A1 (en) * | 2016-12-23 | 2018-06-28 | Universite De Strasbourg | Dynamin 2 inhibitor for the treatment of myotonic dystrophy |
| AU2018210990A1 (en) | 2017-01-23 | 2019-08-29 | Rutgers, The State University Of New Jersey | Compositions for reducing sarcolipin expression and preventing and treating muscular dystrophy and cardiomyopathy and methods of use |
| EP3740575A1 (en) * | 2018-01-15 | 2020-11-25 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
| EP4215614A1 (en) * | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| EP4311546A1 (en) | 2022-07-26 | 2024-01-31 | Dynacure | Combination therapy for myopathies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| EP2119783A1 (en) * | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| CA3066050A1 (en) * | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
| CN103826620A (zh) * | 2011-05-27 | 2014-05-28 | Md制药公司 | 新的治疗方法 |
| CN103764173A (zh) | 2011-07-01 | 2014-04-30 | 得克萨斯系统大学董事会 | 用于治疗骨骼肌病的组合物和方法 |
| EP2862928A1 (en) * | 2013-10-18 | 2015-04-22 | Université de Strasbourg | Dynamin 2 inhibitor for the treatment of centronuclear myopathies |
-
2015
- 2015-04-22 EP EP15305615.5A patent/EP3085785A1/en not_active Withdrawn
-
2016
- 2016-04-22 US US15/568,007 patent/US10822400B2/en active Active
- 2016-04-22 PT PT167220763T patent/PT3286317T/pt unknown
- 2016-04-22 DK DK16722076.3T patent/DK3286317T3/da active
- 2016-04-22 AU AU2016251973A patent/AU2016251973B2/en not_active Ceased
- 2016-04-22 WO PCT/EP2016/059090 patent/WO2016170162A1/en active Application Filing
- 2016-04-22 CA CA2983211A patent/CA2983211A1/en active Pending
- 2016-04-22 CN CN201680023491.9A patent/CN107532169B/zh not_active Expired - Fee Related
- 2016-04-22 EP EP16722076.3A patent/EP3286317B1/en active Active
- 2016-04-22 ES ES16722076T patent/ES2869978T3/es active Active
- 2016-04-22 JP JP2017555366A patent/JP6791877B2/ja active Active
-
2020
- 2020-10-30 US US17/084,686 patent/US20210130447A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180142008A1 (en) | 2018-05-24 |
| JP2018518456A (ja) | 2018-07-12 |
| EP3286317A1 (en) | 2018-02-28 |
| US20210130447A1 (en) | 2021-05-06 |
| EP3085785A1 (en) | 2016-10-26 |
| AU2016251973B2 (en) | 2022-05-26 |
| AU2016251973A1 (en) | 2017-11-09 |
| WO2016170162A1 (en) | 2016-10-27 |
| ES2869978T3 (es) | 2021-10-26 |
| US10822400B2 (en) | 2020-11-03 |
| JP6791877B2 (ja) | 2020-11-25 |
| DK3286317T3 (da) | 2021-05-17 |
| CN107532169A (zh) | 2018-01-02 |
| CN107532169B (zh) | 2021-09-03 |
| EP3286317B1 (en) | 2021-02-24 |
| CA2983211A1 (en) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181679T1 (hr) | Amidni spojevi za liječenje hiv | |
| HK1247202A1 (zh) | 用於治療癌症的化合物 | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| IL275482A (en) | Asketamine for the treatment of depression | |
| PT3286317T (pt) | Inibidor de dinamina 2 para o tratamento de distrofia muscular de duchenne | |
| LT3416957T (lt) | 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui | |
| HK1257247A1 (zh) | 用於預防及治療杜興氏肌肉營養不良症的方法和組合物 | |
| PT3416945T (pt) | Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes | |
| EP3302485A4 (en) | CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNOMES | |
| PL3285755T3 (pl) | Chlorowodorek kreatyny do leczenia choroby Huntingtona | |
| IL253773B (en) | Treatment of dystrophy of the facial, back and arm muscles | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| ZA201606921B (en) | Use of xanthophylls for the treatment of cancers | |
| EP3095398C0 (de) | Patientenspezifisches instrument zur referenzierung von körperteilen | |
| EP3145525A4 (en) | Use of microperoxidases for the treatment of carboxyhemoglobinemia | |
| EP2986301A4 (en) | PHOSPHODIESTERASE 5A INHIBITORS FOR THE TREATMENT OF MUSCLE DYSTROPHY | |
| PL3178521T3 (pl) | Urządzenie do leczenia zintegrowanego rytmu serca | |
| IL262013A (en) | Composition for the treatment of duchenne muscular dystrophy | |
| GB201612920D0 (en) | Composition for the treatment of Duchenne Muscular Dystrophy | |
| GB201605383D0 (en) | Composition for the treatment of duchenne muscular dystrophy | |
| GB201605380D0 (en) | Composition for the treatment of duchenne muscular dystrophy | |
| GB201418513D0 (en) | Compounds for the treatment of muscular dystrophy having improved bioavailability | |
| GB201603886D0 (en) | Compounds for the treatment of type 2 diabetes | |
| GB201603882D0 (en) | Compounds for the treatment of type 2 diabetes |